{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:43:49Z","timestamp":1793313829265,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["AA23023002"],"award-info":[{"award-number":["AA23023002"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277086"],"award-info":[{"award-number":["22277086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2025GXNSFAA069529"],"award-info":[{"award-number":["2025GXNSFAA069529"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bmcl.2025.130315","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:17:05Z","timestamp":1750587425000},"page":"130315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Design, synthesis, and evaluation of 1,3,4-oxadiazole-based EGFR inhibitors"],"prefix":"10.1016","volume":"127","author":[{"given":"Zijun","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6835","key":"10.1016\/j.bmcl.2025.130315_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"issue":"7\u20138","key":"10.1016\/j.bmcl.2025.130315_bb0010","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.biocel.2007.05.008","article-title":"Rational bases for the development of EGFR inhibitors for cancer treatment","volume":"39","author":"Bianco","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130315_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130315_bb0020","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/cmdc.202100166","article-title":"Next-generation kinase inhibitors targeting specific biomarkers in non-small cell lung Cancer (NSCLC): a recent overview","volume":"16","author":"Das","year":"2021","journal-title":"Chemmedchem"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130315_bb0025","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmcl.2025.130315_bb0030","first-page":"S14","article-title":"Erlotinib hydrochloride","author":"Minna","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"5676","key":"10.1016\/j.bmcl.2025.130315_bb0035","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130315_bb0040","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130315_bb0045","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130315_bb0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"issue":"27","key":"10.1016\/j.bmcl.2025.130315_bb0055","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.bmcl.2025.130315_bb0060","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130315_bb0065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-022-01695-2","article-title":"Aumolertinib: a review in non-small cell lung Cancer","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130315_bb0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130315_bb0075","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1080\/14756366.2022.2115036","article-title":"Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review","volume":"37","author":"Wang","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130315_bb0080","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1021\/jm2013248","article-title":"Oxadiazoles in medicinal chemistry","volume":"55","author":"Bostr\u00f6m","year":"2012","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130315_bb0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1570179420666221129153933","article-title":"Recent advancement in synthesis and bioactivities of 1,3,4-oxadiazole","volume":"20","author":"Chaudhary","year":"2023","journal-title":"Curr Org Synth"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130315_bb0090","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.bmcl.2019.06.054","article-title":"Oxadiazole scaffolds in anti-tuberculosis drug discovery","volume":"29","author":"De","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130315_bb0095","article-title":"1,3,4-oxadiazole-based EGFR inhibitors as anticancer therapeutics: SAR study and binding mode of interaction analysis","volume":"14","author":"Samanta","year":"2025","journal-title":"Eur J Med Chem Rep"},{"issue":"10416","key":"10.1016\/j.bmcl.2025.130315_bb0100","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130315_bb0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14740338.2018.1411903","article-title":"A safety evaluation of raltegravir for the treatment of HIV","volume":"17","author":"de Miguel","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130315_bb0110","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1021\/acs.jmedchem.3c02422","article-title":"Discovery of DNL343: a potent, selective, and brain-penetrant eIF2B activator designed for the treatment of neurodegenerative diseases","volume":"67","author":"Craig","year":"2024","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130315_bb0115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3109\/10641968009037161","article-title":"In vitro comparison of the pre- and postsynaptic alpha adrenergic receptor blocking properties of prazosin and tiodazosin (BL5111)","volume":"2","author":"Cohen","year":"1980","journal-title":"Clin Exp Hypertens (1978)"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:22:33Z","timestamp":1752600153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25002240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S0960894X25002240"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130315","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of 1,3,4-oxadiazole-based EGFR inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130315"}}